World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
58560
World Ranking
8736
National Ranking
266

Overview

Mario Campone is affiliated with Grenoble Alpes University in France. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Genetics.

Their main topics of research include:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Glioma Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging

Mario Campone has published research in numerous prominent venues. These frequent publication venues include:

  • Cancer Research
  • Annals of Oncology
  • Journal of Clinical Oncology
  • ESMO Open
  • Clinical Cancer Research

Some recent papers authored by Mario Campone cover a range of significant topics in cancer research and treatment:

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, 2020, The Lancet Oncology
  • Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1, 2020, Annals of Oncology
  • Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial, 2022, The Lancet Oncology
  • Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study, 2021, Annals of Oncology
  • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology

Mario Campone frequently collaborates with several co-authors contributing substantially to their research output. These frequent co-authors include:

  • Fabrice André
  • Jean-Sébastien Frénel
  • Florence Dalenc
  • Paul Cottu
  • Pascal Jézéquel

Best Publications

  • Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Charles E. Geyer;John Forster;Deborah Lindquist;Stephen Chan

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    José Baselga;Mario Campone;Martine Piccart;Howard A. Burris

  • Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    Sandra M. Swain;José Baselga;Sung-Bae Kim;Jungsil Ro

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

    Matthew P. Goetz;Masakazu Toi;Mario Campone;Joohyuk Sohn

  • Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

    Christophe Le Tourneau;Christophe Le Tourneau;Jean Pierre Delord;Anthony Gonçalves;Céline Gavoille

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    Sandra M Swain;Sung-Bae Kim;Javier Cortés;Jungsil Ro

  • A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

    David Cameron;Michelle Casey;Michael Press;Deborah Lindquist

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

  • Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

    José Baselga;Vladimir Semiglazov;Peter van Dam;Alexey Manikhas

  • Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study

    Thomas Bachelot;Gilles Romieu;Mario Campone;Véronique Diéras

  • Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

    Henri Roché;Pierre Fumoleau;Marc Spielmann;Jean-Luc Canon

  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

    Pierre Farmer;Pierre Farmer;Pierre Farmer;Hervé Bonnefoi;Pascale Anderle;David Cameron;David Cameron

  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

    Sylvia Adams;Peter Schmid;Hope H.S. Rugo;Eric Winer

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

    Eva S. Thomas;Henry L. Gomez;Rubi K. Li;Hyun Cheol Chung

  • Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

    M. Piccart;G. N. Hortobagyi;M. Campone;K. I. Pritchard

  • Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

    Martin J. van den Bent;Alba A. Brandes;Roy Rampling;Mathilde C.M. Kouwenhoven

Frequent Co-Authors

Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Véronique Diéras
Véronique Diéras Institute Curie
Pierfranco Conte
Pierfranco Conte University of Padua
Suzette Delaloge
Suzette Delaloge Institut Gustave Roussy
Patrice Viens
Patrice Viens Aix-Marseille University
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Ingrid A. Mayer
Ingrid A. Mayer Vanderbilt University Medical Center
Howard A. Burris
Howard A. Burris Sarah Cannon Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a diverse range of online degrees and career pathways in healthcare. For those seeking a quick entry into the field, fast track medical programs, such as LPN courses, allow you to start working sooner while gaining vital patient care experience.

Specialized careers are also within reach through online education. For example, psych np online programs prepare nurses to address mental health needs and are in high demand across various healthcare settings.

If your interests lie in healthcare leadership or administration, there are many affordable ways to advance. Pursue one of the cheapest mha programs online and gain essential skills for managing healthcare organizations. Alternatively, browse the cheapest mha online programs if you’re comparing master’s degrees with a cost-conscious approach.

Whether you’re starting or advancing your healthcare career, online programs offer flexible, accessible options to meet your professional goals.

Best Scientists Citing Mario Campone

Trending Scientists

Recently Published Articles